{
    "Trade/Device Name(s)": [
        "Contour Next Link Wireless Blood Glucose Monitoring System",
        "Contour Next Blood Glucose Monitoring System"
    ],
    "Submitter Information": "Ascensia Diabetes Care US Inc.",
    "510(k) Number": "K160430",
    "Predicate Device Reference 510(k) Number(s)": [
        "K122370",
        "K121190"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NBW",
        "LFR"
    ],
    "Summary Letter Date": "May 26, 2016",
    "Summary Letter Received Date": "May 27, 2016",
    "Submission Date": "June 21, 2016",
    "Regulation Number(s)": [
        "21 CFR 862.1345"
    ],
    "Regulation Name(s)": [
        "Glucose test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Whole Blood",
        "Capillary blood (fingertip, palm)"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Contour Next Link Wireless Blood Glucose Meter",
        "Contour Next Blood Glucose Meter"
    ],
    "Method(s)/Technology(ies)": [
        "Amperometric detection",
        "FAD-GDH enzymatic reaction"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "System",
        "Meter",
        "Test Strip",
        "Control Solution"
    ],
    "Document Summary": "FDA 510(k) summary for Contour Next Link Wireless and Contour Next Blood Glucose Monitoring Systems for home use in diabetes management",
    "Indications for Use Summary": "OTC blood glucose monitoring systems for single-patient self-testing using fresh capillary whole blood from fingertip or palm; aids diabetes control; not for diagnosis, screening, or neonatal use",
    "fda_folder": "Clinical Chemistry"
}